Temple City, CA, United States of America

Marvin Lin

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Amphastar Pharmaceuticals, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Marvin Lin in Injectable Epinephrine Formulations

Introduction

Marvin Lin is an accomplished inventor based in Temple City, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of injectable epinephrine formulations. His work focuses on enhancing the stability and retention of epinephrine over extended storage periods.

Latest Patents

Marvin Lin holds a patent for "Injectable epinephrine formulations demonstrating stability over time." This innovative formulation includes 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt, along with a tonicity regulating agent, pH adjusting agents, and other stabilizing components. The formulation is designed to maintain an API recovery of 94.5% or more after at least 30 months of storage under defined long-term conditions.

Career Highlights

Marvin Lin is currently associated with Amphastar Pharmaceuticals, Inc., where he continues to work on groundbreaking pharmaceutical formulations. His expertise in the field has led to advancements that benefit both healthcare providers and patients.

Collaborations

Throughout his career, Marvin has collaborated with notable colleagues, including Rong Zhou and Mary Zi-ping Luo. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Marvin Lin's contributions to injectable epinephrine formulations exemplify the importance of innovation in the pharmaceutical industry. His work not only enhances the stability of essential medications but also improves patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…